Cost-effectiveness of rapid susceptibility testing against second-line drugs for tuberculosis

International Journal of Tuberculosis and Lung Disease

Volumn 18, Issue 6, 2014, Pages

  Dowdy, David W ^a   Van'T Hoog, A ^b   Shah, M ^c   Cobelens, F ^b,d  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b AMSTERDAM INSTITUTE FOR GLOBAL HEALTH AND DEVELOPMENT   (Netherlands)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d KNCV TUBERCULOSIS FOUNDATION   (Netherlands)

Author keywords

Diagnostic methods and procedures; Drug resistance; Economic models; Tuberculosis

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; CAPREOMYCIN; CYCLOSERINE; ISONIAZID; KANAMYCIN; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ALGORITHM; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM CULTURE; CLINICAL ARTICLE; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DRUG SUSCEPTIBILITY TESTING; ECONOMIC EVALUATION; HUMAN; INTERMETHOD COMPARISON; LOWEST INCOME GROUP; MORTALITY; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; RAPID TEST; SECOND LINE TUBERCULOSIS DRUG; SENSITIVITY AND SPECIFICITY; STANDARDIZATION; TUBERCULOSIS; ASIA; COST BENEFIT ANALYSIS; DECISION SUPPORT SYSTEM; DECISION TREE; DRUG COST; ECONOMICS; EVALUATION STUDY; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; HEALTH CARE COST; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PREDICTIVE VALUE; STATISTICAL MODEL; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ALGORITHMS; ANTITUBERCULAR AGENTS; ASIA; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DECISION TREES; DRUG COSTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; HEALTH CARE COSTS; HUMANS; MICROBIAL SENSITIVITY TESTS; MODELS, ECONOMIC; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84901270685     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.13.0776     Document Type: Article

References (24)

1. World Health Organization. Same-day diagnosis of tuberculosis by microscopy: policy statement. WHO/HTM/TB/2011.7. Geneva, Switzerland: WHO, 2011.
2. Steingart K R, Sohn H, Schiller I, et al. Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev 2013; 1: CD009593.
3. Niemz A, Boyle D S. Nucleic acid testing for tuberculosis at the point-of-care in high-burden countries. Expert Rev Mol Diagn 2012; 12: 687-701.
4. Joh J S, Lee CH, Lee J E, et al. The interval between initiation of anti-tuberculosis treatment in patients with culture-positive pulmonary tuberculosis and receipt of drug-susceptibility test results. J Korean Med Sci 2007; 22: 26-29.
5. Ahuja S D, Ashkin D, Avendano M, et al. Multidrug-resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLOS MED 2012; 9: e1001300.
6. Boehme C C, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 2010; 363: 1005-1015.
7. Pai M. Diagnostics for tuberculosis: what test developers want to know. Expert Rev Mol Diagn 2013; 13: 311-314.
8. Lew W, Pai M, Oxlade O, Martin D, Menzies D. Initial drug resistance and tuberculosis treatment outcomes: systematic review and meta-analysis. Ann Intern Med 2008; 149: 123-134. (Pubitemid 352008599)
9. Vassall A, van Kampen S, Sohn H, et al. Rapid diagnosis of tuberculosis with the xpert mtb/rif assay in high burden countries: a cost-effectiveness analysis. PLOS MED 2011; 8: e1001120.
10. World Health Organization. Tuberculosis country profiles. Geneva, Switzerland: WHO, 2014. http://www.who.int/tb/country/data/profiles/en/index. html. Accessed March 2014.
11. World Health Organization. Global tuberculosis report, 2012. WHO/HTM/TB/2012.6. Geneva, Switzerland: WHO, 2012.
12. Menzies D, Benedetti A, Paydar A, et al. Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: a systematic review and meta-analysis. PLOS MED 2009; 6: e1000150.
13. Zhao Y, Xu S, Wang L, et al. National survey of drug-resistant tuberculosis in China. N Engl J Med 2012; 366: 2161-2170.
14. Salomon J A, Vos T, Hogan D R, et al. Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2129-2143.
15. Weinstein M C, Siegel J E, Gold M R, Kamlet M S, Russell L B. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 1996; 276: 1253-1258. (Pubitemid 26337709)
16. Jenkins H E, Zignol M, Cohen T. Quantifying the burden and trends of isoniazid resistant tuberculosis, 1994-2009. PLOS ONE 2011; 6: e22927.
17. Liu CH, Li L, Chen Z, et al. Characteristics and treatment outcomes of patients with MDR and XDR tuberculosis in a TB referral hospital in Beijing: a 13-year experience. PLOS ONE 2011; 6: e19399.
18. Kim H R, Hwang S S, Kim H J, et al. Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis. Clin Infect Dis 2007; 45: 1290-1295.
19. Tiemersma EW, van der Werf M J, Borgdorff M W, Williams B G, Nagelkerke N J. Natural history of tuberculosis: duration and fatality of untreated pulmonary tuberculosis in HIV negative patients: a systematic review. PLOS ONE 2011; 6: e17601.
20. World Health Organization. Global Health Observatory Data Repository. Geneva, Switzerland: WHO, 2013. http://apps.who.int/ghodata/. Accessed March 2014.
21. Ling D I, Flores L L, Riley LW, Pai M. Commercial nucleic-acid amplification tests for diagnosis of pulmonary tuberculosis in respiratory specimens: meta-analysis and meta-regression. PLOS ONE 2008; 3: e1536.
22. Wilson M. Recent advances in the laboratory detection of Mycobacterium tuberculosis complex and drug resistance. Clin Infect Dis 2011; 52: 1350-1355.
23. Yagui M, Perales M T, Ascencios L, et al. Timely diagnosis of MDR-TB under program conditions: is rapid drug susceptibility testing sufficient? Int J Tuberc Lung Dis 2006; 10: 838-843. (Pubitemid 44197842)
24. World Health Organization. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF system for the diagnosis of pulmonary and extrapulmonary TB in adults and children. Policy update. WHO/HTM/TB/2013. 14. Geneva, Switzerland: WHO, 2013. http://www.stoptb.org/wg/gli/assets/documents/ WHO%20Policy%20Statement%20on%20Xpert%20MTB- RIF%202013%20pre%20publication%2022102013.pdf. Accessed March 2014.